Last reviewed · How we verify
V114-A
At a glance
| Generic name | V114-A |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- V114 and Acute Otitis Media (V114-032/PNEU-ERA) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) (PHASE1)
- Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PHASE3)
- A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V114-A CI brief — competitive landscape report
- V114-A updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI